Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 12.20
- Piotroski Score 7.00
- Grade Overweight
- Symbol (EW)
- Company Edwards Lifesciences Corporation
- Price $68.25
- Changes Percentage (1.65%)
- Change $1.11
- Day Low $66.16
- Day High $68.39
- Year High $96.12
Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides the PASCAL and Cardioband transcatheter valve repair systems for minimally-invasive therapy. In addition, it offers surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; KONECT RESILIA, a pre-assembled aortic tissue valved conduit for patients who require replacement of the valve, root, and ascending aorta; and HARPOON Beating Heart Mitral Valve Repair System for patients with degenerative mitral regurgitation. Further, the company provides critical care solutions, including advanced hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 10/23/2024
- Fiscal Year End N/A
- Average Stock Price Target $87.50
- High Stock Price Target $140.00
- Low Stock Price Target $70.00
- Potential Upside/Downside N/A
- Consensus Rating Neutral
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) $2.32
- Trailing P/E Ratio 37.99
- Forward P/E Ratio 37.99
- P/E Growth 37.99
- Net Income $1.40 B
Income Statement
Quarterly
Annual
Latest News of EW
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
UFC 306 Preview, Odds, Picks And Predictions: Ortega Vs. Lopes
UFC 306 on September 14 features title fights headlined by O'Malley vs. Dvalishvili and Grasso vs. Shevchenko. Ortega vs. Lopes is a highly anticipated bout on the card, with Lopes being the favorite....
By Forbes | 10 hours ago -
Trump won't say if he wants Ukraine to win, a warning as U.S. offers new show of support
Secretary of State Antony Blinken's visit to Kyiv signals a potential shift in U.S. policy on Ukraine's use of long-range weapons in the conflict with Russia. This visit contrasts with former Presiden...
By NBC News | 10 hours ago -
PT Bank Pan Indonesia Tbk (PNBN.JK) Stock Price, News, Quote & History - Yahoo Finance
ANZ Group Holdings Ltd. is looking to sell its stake in PT Bank Pan Indonesia to streamline operations. The Australian lender is considering reviving the sale, as reported by Bloomberg sources....
By Yahoo! Finance | 11 hours ago
